Medication info
Regabacapsule 75 mg (Pregabalin)

Regabacapsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Withus Pharmaceutical Co., Ltd.
Appearance
Hard capsule with a reddish-brown upper part and a white lower part containing white or pale yellow powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201603420 · Approved 2016.06.14 · Insurance code 660702970

Summary

Main use
Treatment of neuropathic pain, treatment of fibromyalgia, and adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section '5. Patients with renal impairment'). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this medicine may be 150 mg daily. Depending on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: The initial dose of this medicine may be 150 mg daily. Depending on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section '4. Discontinuation of treatment'). 2. Epilepsy Adults: The initial dose of this medicine may be 150 mg daily. Depending on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily); depending on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Since its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosing regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: Supplemental dose refers to an additional single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
7. Pediatric and adolescent patients Use is not recommended in children under 12 years of age or adolescent patients aged 12 ~17 years because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Withus Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, treatment of fibromyalgia, and adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This drug is used to treat peripheral and central neuropathic pain in adults. It also helps as an adjunct in patients with epilepsy experiencing partial seizures. Moreover, it is used to alleviate the symptoms of fibromyalgia. Overall, it effectively aids in improving nerve-related pain and seizures.

How to take

Adult dose

Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section '5. Patients with renal impairment'). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this medicine may be 150 mg daily. Depending on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: The initial dose of this medicine may be 150 mg daily. Depending on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section '4. Discontinuation of treatment'). 2. Epilepsy Adults: The initial dose of this medicine may be 150 mg daily. Depending on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily); depending on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Since its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosing regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: Supplemental dose refers to an additional single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

7. Pediatric and adolescent patients Use is not recommended in children under 12 years of age or adolescent patients aged 12 ~17 years because there are insufficient safety and efficacy data.

Precautions

This drug may increase the risk of suicidal thoughts or behaviors, so if there are signs of depression or mood changes during treatment, it is crucial to inform your healthcare provider immediately. It is not advisable to use this drug if there is a hypersensitivity to it or if there are genetic problems such as lactose intolerance. Diabetic patients may experience difficulty controlling blood sugar levels due to weight gain, which could necessitate adjustments in diabetes medication dosages. If symptoms of angioedema occur, the drug should be discontinued immediately and a doctor consulted. Elderly patients should be cautious during initial administration due to the risk of falls caused by dizziness or drowsiness. Blurred vision or changes in vision may occur, and abnormal symptoms should be reported. Abrupt discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headaches, and anxiety, so it should be tapered off per doctor's instructions. Patients with a history of substance abuse may have a higher risk of misuse of this drug, hence it should be administered with caution. Patients with impaired kidney function may require dosage adjustments. Those with cardiac conditions should be cautious when taking this medication. Concomitant use with opioid analgesics could increase the risk of central nervous system depression, so caution is advised. Patients with respiratory or neurological conditions or the elderly may be at risk for severe respiratory depression, so consulting healthcare providers is essential. During early pregnancy, there is a risk of fetal malformations, so women who are pregnant or planning to become pregnant must consult a physician. While breastfeeding, this drug can pass into breast milk; hence, the option of discontinuing breastfeeding or the drug should be considered. There is a risk of accidents due to dizziness and drowsiness when driving or operating machinery, so caution should be exercised until symptoms improve. Severe skin reactions can occur rarely; therefore, if a skin rash or swelling appears, immediate cessation of the drug and a visit to the hospital are required. In case of overdose, confusion, drowsiness, and depressive symptoms may arise, and treatments such as dialysis may be required if necessary. This drug should be kept out of reach of children, and it is advisable not to transfer it to other containers.

Side effects

  • Suicidal impulses
  • suicidal behavior
  • depression
  • angioedema
  • facial swelling
  • perioral edema
  • upper respiratory edema
  • dizziness
  • drowsiness
  • loss of consciousness
Show 200 more
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • sadness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • spatial disorientation
  • irritability
  • feelings of happiness
  • decreased libido
  • depersonalization
  • sexual arousal disorder
  • agitation
  • mood disturbances
  • emotional blunting
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory deficits
  • sedation
  • hypersomnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • reflex decrease
  • movement abnormalities
  • psychomotor agitation
  • positional vertigo
  • sensory hyperesthesia
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory abnormalities
  • loss of taste
  • writing disability
  • diplopia
  • dry eye
  • eye inflammation
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • during vibration
  • changes in depth perception
  • strabismus
  • brightness of vision
  • vertigo
  • auditory hyperesthesia
  • first-degree AV block
  • tachycardia
  • bradycardia
  • tachyarrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • meteorism
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory decrease
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falling
  • feeling intoxicated
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • depression
  • agitation
  • restlessness
  • deterioration of seizures
  • gastrointestinal disturbances
  • tinnitus
  • sleep disorders
  • skin diseases
  • increased BUN
  • blood in stool
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly closed container to prevent air or moisture ingress. Additionally, it is best stored at a temperature between 15 degrees and 30 degrees Celsius, avoiding extremes of cold or heat.

Appearance and packaging

Appearance

Hard capsule with a reddish-brown upper part and a white lower part containing white or pale yellow powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.